AADI News and Press, Aadi Bioscience Inc. From 03/28/23

2023-03-28 11:34:48 ET The following slide deck was published by Aadi Bioscience, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Aadi Bioscience, Inc. 2022 Q4 - Results - Earnings Call Presentation

2023-03-28 08:05:06 ET Aadi Bioscience press release ( NASDAQ: AADI ): Q4 GAAP EPS of -$0.52 beats by $0.19 . Revenue of $5.23M (+423.0% Y/Y) beats by $0.58M . Cash, cash equivalents and short-term investments as of December 31, 2022 were $172.6 million as comp...

Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Corporate Update PR Newswire Total revenue on FYARRO® sales of $15.2 million for FY 2022 PRECISION 1 trial preliminary data expected in the second quarter of 202...

2023-03-27 15:35:42 ET Aadi Bioscience ( NASDAQ: AADI ) is scheduled to announce Q4 earnings results on Tuesday, March 28th, before market open. The consensus EPS Estimate is -$0.72 (+6.5% Y/Y) and the consensus Revenue Estimate is $4.65M (+365.0% Y/Y). For further d...

Aadi Bioscience Appoints Mohammad Hirmand, M.D. to Board of Directors PR Newswire LOS ANGELES , March 27, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision t...

Aadi Bioscience Presents Clinical Data from PRECISION 1 and AMPECT Trials at the Society of Gynecological Oncology (SGO) Annual Meeting on Women's Cancer PR Newswire LOS ANGELES , March 26, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-s...

Aadi Bioscience to Report Fourth Quarter and Full-Year 2022 Results and Corporate Update PR Newswire Company to Host Conference Call and Webcast on March 28, 2023 LOS ANGELES , March 15, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a com...

2023-03-06 23:10:33 ET Summary AADI is a commercial stage company with a potential label expansion ahead. It is adequately funded, run by expert management, and has a major catalyst next year. All told, AADI looks good. Aadi Bioscience ( AADI ) is a commercial st...

Aadi Bioscience ( NASDAQ: AADI ) announces that Brendan Delaney has resigned for personal reasons from his position as CEO, President, and member of the Board of Directors of the Company. Scott Giacobello, currently the Company's CFO, has been appointed to serve as Interim CEO and...

Aadi Bioscience Announces Leadership Transition PR Newswire LOS ANGELES , March 3, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with alterati...